annalise.ai launches next-generation CT brain AI solution for clinical use in the UK

Global medical imaging AI leader annalise.ai has launched Annalise Enterprise CTB, an AI-enabled Software as a Medical Device (SaMD) decision support solution for non-contrast CT brain studies to the UK.

Annalise Enterprise CTB is a clinically comprehensive decision support AI solution with an innovative algorithm that can identify 130 imaging findings, including a wide range of conditions that require time sensitive interventions. It’s designed to be an assistive clinical tool, empowering radiologists with a ‘second pair of eyes’ to help them improve diagnostic accuracy and health outcomes for patients.

Dr Rick Abramson, chief medical officer of annalise.ai, said: “Annalise Enterprise CTB represents an evolutionary leap forward in AI technology for neuroimaging. Whereas most other AI products for head CT can recognise only a small handful of conditions, Annalise CTB assists the radiologist with 130 imaging findings – which means more support for the radiologist and a bigger impact on patient care. In our controlled product launch, we have already seen countless examples of critical pathology that could have been missed but were successfully identified by Annalise CTB.”

In addition to assisting with the detection of imaging findings, Annalise Enterprise CTB can streamline patient care workflows. Analysing non-contrast head CT examinations as they are acquired, the solution can provide a notification signal for urgent cases, helping radiologists to triage high-priority cases in need of rapid action.

The support from Annalise Enterprise CTB could be particularly impactful to overstretched radiology residents reporting out-of-hours at teaching hospitals and in areas experiencing challenging radiologist capacity constraints. The solution is currently in use in Australia and clinically available in Australia, New Zealand and the UK.

This news story has been sponsored by the companies concerned and does not represent the views or opinions of RAD Magazine.  Visit our dedicated ECR conference page to find out more.